I suspect that a responsible medical team would use this technology to alter treatment options, or at least discuss those options with the patient. Of course, that will involve discussing with the patient the likely prognosis per option. Not easy, but these conversations already happen. The hard part is this transiting phase we are entering, with this advance: we can detect organ failure with greater sensitivity, but we can't do anything about it (as I understand it).
I trust that medical researchers will next want to investigate how this advance might improve survival/morbidity by altering interventions and management. Perhaps it will allow greater certainty regarding specific regimens, perhaps it will allow earlier detection.
Transitions are hard, probably unavoidable, and I hope this one has a beneficial outcome.